Peptide Informed Consent Guide
A practical framework for explaining peptide therapy, documenting patient understanding, and deciding when you need peptide-specific, compounded-medication, or off-label consent addenda.
Why this matters
Informed consent is where peptide education becomes real clinical risk management.
For peptide therapy, the informed-consent conversation often carries more weight than it does in more standardized prescribing workflows. Patients may be hearing about peptides from social media, influencers, or branded weight-loss ads long before they reach your practice.
Your consent process is the moment where you re-anchor the conversation in clinical rationale, real-world limitations, regulatory context, and patient-specific risk. That is especially important when therapy is compounded, off-label, or still poorly understood by the patient.
Use this page when
- General peptide initiation for a new patient starting therapy
- GLP-1 starts, titration counseling, or switch from branded to compounded product
- Any compounded peptide prescription that requires patient understanding of 503A or 503B sourcing context
- Off-label prescribing where the indication or regimen is not specifically FDA-approved
The four pillars of a strong peptide consent process
Clinical rationale
Document the indication, expected benefit, and why peptide therapy is being considered for this patient at this point in care.
Risk disclosure
Explain common adverse effects, serious risks, contraindications, and the practical limitations of the evidence base.
Product status
Clarify when use is off-label, when a product is compounded, and how that differs from FDA-approved commercial products.
Patient understanding
Record that the patient had the opportunity to ask questions, understood alternatives, and consented voluntarily.
Common consent failure points
- Using a generic med-spa waiver that never addresses peptide-specific risks
- Not documenting compounded status or off-label use clearly enough for a skeptical patient or reviewer
- Explaining benefits in detail while leaving alternatives and limitations vague
- Failing to refresh consent when therapy changes significantly over time
A practical workflow you can standardize
1. Start with a base consent
Use a general peptide therapy consent as the foundation for every new-start discussion so the process is consistent across clinicians and staff.
2. Add peptide-specific addenda
Layer on GLP-1, compounded medication, or off-label disclosures when the treatment plan requires more specific risk and regulatory context.
3. Align the chart note
Your chart note and consent packet should tell the same story: indication, alternatives discussed, patient questions answered, and next-step plan.
4. Refresh when treatment changes
Revisit informed consent when the indication changes, the peptide changes, the source changes, or the patient moves into a higher-risk regimen.
Recommended packet structure
Build one reusable packet instead of improvising each conversation.
For most practices, the cleanest operational setup is a base peptide consent plus one or more addenda depending on the therapy. That lowers legal drift, makes staff training easier, and keeps the charting workflow consistent.
Suggested packet
- 1. General peptide therapy consent
- 2. GLP-1 addendum when applicable
- 3. Off-label disclosure when applicable
- 4. Compounded medication disclosure when applicable
Start with templates, then customize for your practice
Use the free consent forms as working drafts, pair them with the regulatory quick reference, and adapt them with your counsel for state-specific and specialty-specific needs.